Alpha Cognition Inc ACOG

VANCOUVER, British Columbia & GRAPEVINE, Texas, October 02, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a

VANCOUVER, British Columbia & GRAPEVINE, Texas, October 01, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan

Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation. Net product revenue increased 71% q/q to $6.0M on 37% bottle growth, with no material stocking benefit and downstream PBM implementation unchanged...

The fair value price target for Alpha Cognition has shifted from about US$14.67 to US$16.75, which places the stock in a higher valuation range than before. Recent analyst commentary links this move to expectations around Zunveyl, including early launch progress, payer access, and the potential to address tolerability issues seen with existing Alzheimer’s therapies. As you read on, you will see how these factors fit into the evolving Alpha Cognition story and how to track new information as...

Moby summary of Alpha Cognition Inc. Common Stock's Q2 2026 earnings call

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, British Columbia & DALLAS, August 13, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

VANCOUVER, British Columbia & DALLAS, August 03, 2026--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close.

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, British Columbia & GRAPEVINE, Texas, July 29, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease.

Geopolitics have been making headlines again – war in the Middle East and uncertainty in the price of oil are stirring up the headwinds. Yet, the S&P 500 has remained resilient, supported by strong corporate earnings. During the first-quarter earnings season, tech companies helped drive overall year-over-year earnings growth of 28.6%, the strongest quarter since late 2021, and expectations remain high for the second quarter, with FactSet forecasting earnings growth above 20% for a second consecu